Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Angle Share News (AGL)
AGL Share
Price
AGL Share
News
AGL Share
Chat
AGL Share
Trades37
AGL
Live RNS
AGL Share
Charts
AGL Broker
Ratings
AGL Directors
Deals
AGL Financial
Diary
AGL
Fundamentals
AGL Short
Positions
AGL
Media
AGL Company
Research
AGL Company
Timeline
- There is currently no data for AGL
IN BRIEF: Angle highlights supportive data for DNA analysis tool
Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.
Current stock price: 17.85 pence, down 8.5% in London on Monday
12-month change: down 42%
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
Latest AGL News
- Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
11 Feb 2020 - Angle upbeat on research into Parsortix with melanoma patients
11 Feb 2020 - Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance
30 Jan 2020 - UK Earnings, Trading Statements Calendar - Next 7 Days
23 Jan 2020 - Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter
22 Jan 2020 - Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma
7 Nov 2019 - Angle Submits Positive Test Results For Parsortix System To US FDA
31 Oct 2019 - Angle upbeat on patent grant for prostate cancer blood assessment
4 Oct 2019
Related News
IN BRIEF: Angle names Peter Collins as interim CEO
(Alliance News) - Angle PLC - Guildford, England-based liquid biopsy company, which is to be renamed CelLBxHealth PLC - Appoints Peter Collins as inte...
Angle touts planned name and strategy change, Groen turns executive
(Alliance News) - Angle PLC shares fell on Wednesday, after it announced plans to rename itself CelLBxHealth PLC and "[pursue] a revised strategy", wi...
IN BRIEF: Angle CEO and finance lead step down after shareholder talks
Angle PLC - Guildford, England-based liquid biopsy company - Says that, following talks with an unnamed "significant shareholder", Chief Executive Off...
Angle News
Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
Study Finds Angle's Parsortix Can Predict Melanoma Sufferers Survival
Angle upbeat on research into Parsortix with melanoma patients
(Sharecast News) - Liquid biopsy company Angle announced on Tuesday that a customer, the Edith Cowan University in Perth, Western Australia, has publi...
Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance
Angle Loss Widens As It Eyes US Parsotix Cancer Treatment Clearance
UK Earnings, Trading Statements Calendar - Next 7 Days
UK Earnings, Trading Statements Calendar - Next 7 Days
Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter
Angle Eyes US Consent For Parsortix Cancer Medication In Third Quarter
Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma
Angle Gets Study Results Demonstrating Use Of Parsortix In Melanoma
Angle Submits Positive Test Results For Parsortix System To US FDA
Angle Submits Positive Test Results For Parsortix System To US FDA
Angle upbeat on patent grant for prostate cancer blood assessment
(Sharecast News) - Liquid biopsy company Angle announced on Friday that the Queen Mary University of London (QMUL) European patent covering the measur...
Follow the stocks
